Form 4: Twist Bioscience CEO Executes Mandatory Stock Sale for Tax Obligations
Insider Transaction Report
Twist Bioscience CEO Emily M. Leproust sold 476 shares of common stock to cover tax withholding obligations related to vested restricted stock units.
Summary
- Emily M. Leproust, Chief Executive Officer and Director of Twist Bioscience Corp (TWST), reported a transaction involving the sale of company common stock.
- On July 2, 2025, 476 shares of common stock were disposed of at a price of $36.193 per share.
- This sale was mandated by Twist Bioscience's equity incentive plans as a 'sell to cover' transaction to satisfy tax withholding obligations in connection with the vesting of Restricted Stock Units, and does not represent a discretionary trade by Ms. Leproust.
- Following this transaction, Ms. Leproust beneficially owns 645,306 shares of common stock directly.
- The filing also details several employee stock options held by Ms. Leproust with various exercise prices and vesting schedules, including options exercisable at $5.95, $8.82, $26.66, $23.33, and $67.85.
Sentiment
Score: 5
Explanation: The sentiment is neutral as the reported transaction is a mandatory 'sell to cover' for tax purposes, not a discretionary sale indicating a change in management's confidence or outlook.
Positives
- The stock sale was non-discretionary, specifically for tax withholding, which typically does not signal a lack of confidence in the company by the insider.
Risks
- Intentional misstatements or omissions of facts in SEC filings constitute Federal Criminal Violations.
Future Outlook
This Form 4 filing primarily reports an insider transaction and does not contain forward-looking statements or guidance regarding the company's future performance or strategic outlook.
Management Comments
- The sales are mandated by the Issuer's election under its equity incentive plans to require the satisfaction of a tax withholding obligation to be funded by a 'sell to cover' transaction and do not represent discretionary trades by the Reporting Person.
Industry Context
This filing is a routine disclosure of an insider stock transaction, specifically a 'sell to cover' for tax purposes, which is a common occurrence for executives receiving equity compensation across various industries. It does not provide insights into broader industry trends or competitive dynamics.
Related Party Transactions
- The reported transaction is a sale of shares to the issuer to cover tax withholding obligations related to the vesting of Restricted Stock Units, a standard mechanism within equity incentive plans.
Stakeholder Impact
- Shareholders: Minimal direct impact as this is a routine, non-discretionary tax-related sale by an executive, not indicative of a change in company fundamentals or management's view on the stock.
- Employees: The transaction highlights the standard process for managing equity compensation and tax obligations for executives.
Next Steps
- Continued vesting of various employee stock options held by the reporting person according to their respective schedules.
Key Dates
| Date | Description |
|---|---|
| 09/01/2016 | Vesting commencement for an employee stock option (25% vested, then 1/48th monthly). |
| 09/28/2017 | Vesting commencement for an employee stock option (10% vested). |
| 09/28/2018 | Additional vesting for an employee stock option (15% vested). |
| 10/31/2019 | Vesting commencement for an employee stock option (20% vested, then 1/60th monthly). |
| 09/01/2020 | Grant date for performance stock options. |
| 10/24/2020 | Vesting commencement for an employee stock option (25% vested, then 1/48th monthly). |
| 12/19/2022 | Performance stock options vested and became exercisable due to performance criteria being met. |
| 07/02/2025 | Date of common stock disposition (sale). |
| 07/07/2025 | Signature date of the filing by Attorney-in-Fact. |
| 09/28/2025 | Expiration date for an employee stock option with a $5.95 exercise price. |
| 09/28/2027 | Expiration date for an employee stock option with an $8.82 exercise price. |
| 11/18/2028 | Expiration date for an employee stock option with a $26.66 exercise price. |
| 10/23/2029 | Expiration date for an employee stock option with a $23.33 exercise price. |
| 08/31/2030 | Expiration date for performance stock options with a $67.85 exercise price. |
Keywords
Twist Bioscience, TWST, SEC Form 4, Insider Transaction, Emily M. Leproust, CEO, Stock Sale, Restricted Stock Units, Tax Withholding, Employee Stock Options
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.